Leerink Partners upgrades enGene Therapeutics to Outperform from Market Perform, sets price target at $5

Leerink Partners upgraded enGene Therapeutics to Outperform from Market Perform, setting a $5 price target. This implies a 119.3% upside from the Nov 12 close of $2.28.

Original reporting
Published Nov 13, 2026, 12:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 12:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Leerink Partners upgrades enGene Therapeutics to Outperform from Market Perform, sets price target at $5 — source image
Decision brief

The 30-second read

$ENGNBullishMed
01

Why it matters

The upgrade may trigger a short‑term rally, but long‑term performance hinges on pipeline milestones.

02

Market read

Analyst upgrade with a high price target provides a fresh catalyst for a low‑float stock.

03

What to watch

No disclosed clinical data; price target relies on future expectations.

Relevance 7/10Novelty 7/10Timing: today

Background

enGene Therapeutics is a micro‑cap biotech focused on gene‑editing therapies.

Company-level read

Ticker impact

$ENGNBullishHigh confidence
Context

Leerink Partners upgraded enGene Therapeutics to Outperform and set a $5 price target, implying 119% upside.

Expected impact

likely upward pressure as investors price in the new target

Evidence & confidence

The upgrade is a fresh, primary disclosure and the target represents a large upside for a micro‑cap, prompting short‑term buying.

Market effects

May lift sentiment for small‑cap biotech peers.

Limited to U.S. biotech investors.

Low

Counterpoint

The upgrade could be premature if upcoming trial data disappoints.

Key entities

  • Leerink Partners

    Equity research firm issuing the upgrade.

  • enGene Therapeutics

    Biotech firm receiving the upgrade.

Related articles

$ENGNHighAI 8/10

Engene stock maintains Outperform rating on bladder cancer data

Raymond James reiterated an Outperform rating and $4.00 price target on Engene Holdings (ENGN) after positive bladder cancer trial data. The stock is down 79% from its 52-week high but has a strong balance sheet. The FDA meeting feedback and trial results suggest potential approval by 2026. Other analysts also commented on the company's prospects.

$ENGNLow

enGene Therapeutics Inc. (ENGN): Results of Operations and Financial Condition

enGene Therapeutics Inc. (ENGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Corporate Presentation Non-Viral Genetic Medicine Disclaimers Cautionary Statement Regarding Forward-Looking Statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws and "forward-looking information" within the mea